Curis, Inc. (NASDAQ:CRIS) was the recipient of a significant drop in short interest in September. As of September 30th, there was short interest totalling 287,500 shares, a drop of 41.2% from the August 30th total of 489,100 shares. Currently, 1.1% of the shares of the stock are sold short. Based on an average daily volume of 199,600 shares, the days-to-cover ratio is presently 1.4 days.
A number of institutional investors and hedge funds have recently modified their holdings of the stock. Renaissance Technologies LLC lifted its position in Curis by 20.6% in the second quarter. Renaissance Technologies LLC now owns 1,191,419 shares of the biotechnology company’s stock worth $2,216,000 after buying an additional 203,590 shares during the last quarter. Fosun International Ltd lifted its position in Curis by 46.6% in the second quarter. Fosun International Ltd now owns 581,834 shares of the biotechnology company’s stock worth $1,065,000 after buying an additional 184,965 shares during the last quarter. BlackRock Inc. lifted its position in Curis by 15.2% in the second quarter. BlackRock Inc. now owns 487,816 shares of the biotechnology company’s stock worth $908,000 after buying an additional 64,262 shares during the last quarter. Cetera Advisor Networks LLC bought a new stake in Curis in the second quarter worth $42,000. Finally, JPMorgan Chase & Co. bought a new stake in Curis in the second quarter worth $40,000. Institutional investors own 23.64% of the company’s stock.
Separately, ValuEngine downgraded Curis from a “buy” rating to a “hold” rating in a research report on Tuesday, August 6th.
CRIS traded up $0.01 during trading on Friday, reaching $2.08. The company had a trading volume of 134,340 shares, compared to its average volume of 142,998. The business has a 50 day simple moving average of $2.12 and a 200-day simple moving average of $1.94. Curis has a 52 week low of $0.60 and a 52 week high of $2.90.
Curis (NASDAQ:CRIS) last issued its quarterly earnings results on Tuesday, August 6th. The biotechnology company reported ($0.22) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.19) by ($0.03). The company had revenue of $2.09 million during the quarter.
Curis, Inc, a biotechnology company, focuses on the development and commercialization of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include CUDC-907, an oral dual inhibitor of HDAC and PI3K enzymes, which is in Phase II clinical trial for the treatment of patients with MYC-altered diffuse large B-cell lymphoma and solid tumors; CA-170, an oral small molecule drug candidate that is in Phase I clinical trial for treating patients with advanced solid tumors and lymphomas; CA-4948, an oral small molecule drug candidate, which is in Phase I clinical trial for the treatment of non-hodgkin lymphomas; and CA-327, an oral small molecule drug candidate that is in preclinical stage for the treatment of cancers.
Read More: Hedge Funds – Risk or Reward?
Receive News & Ratings for Curis Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Curis and related companies with MarketBeat.com's FREE daily email newsletter.